Duchenne Muscular Dystrophy - Pipeline Review, H2 Pharmaceutical Research Report 2017

Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Duchenne Muscular Dystrophy - Pipeline Review, H2 2017”. Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome.

Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305512

It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 12, 11, 2, 53 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 1 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/duchenne-muscular-dystrophy-pipeline-review-h2-2017-report.html

Table of Contents
Table of Contents 2
Introduction 5
Duchenne Muscular Dystrophy - Overview 6
Duchenne Muscular Dystrophy - Therapeutics Development 7
Duchenne Muscular Dystrophy - Therapeutics Assessment 21
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development 31
Duchenne Muscular Dystrophy - Drug Profiles 56
Duchenne Muscular Dystrophy - Dormant Projects 270
Duchenne Muscular Dystrophy - Discontinued Products 273
Duchenne Muscular Dystrophy - Product Development Milestones 274
Appendix 284

List of Tables
Number of Products under Development for Duchenne Muscular Dystrophy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Duchenne Muscular Dystrophy - Pipeline by 4P-Pharma SAS, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Beech Tree Labs Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, H2 2017
Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by CRISPR Therapeutics, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Debiopharm International SA, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Editas Medicine Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Eloxx Pharmaceuticals Ltd, H2 2017
Duchenne Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Duchenne Muscular Dystrophy - Pipeline by FibroGen Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Genethon SA, H2 2017
Duchenne Muscular Dystrophy - Pipeline by GTx Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by GW Pharmaceuticals Plc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Italfarmaco SpA, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by La Jolla Pharmaceutical Company, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Lexicon Pharmaceuticals Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Marathon Pharmaceuticals LLC, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Marina Biotech Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Merck KGaA, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Mitobridge Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by Mitochon Pharmaceuticals Inc, H2 2017
Duchenne Muscular Dystrophy - Pipeline by N-Gene Research Laboratories Inc, H2 2017

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1305512

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.